Warby Parker Inc.
WRBY Healthcare Medical Instruments & Supplies
Warby Parker Inc.’s revenue for fiscal 2025 (year ended December 2025) was $871.9 million, up 13.0% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- −20.0%
- Free cash flow
- −30.3%
Quarter to September 2026, against a year earlier
Follow WRBY
Alert me
Warby Parker Inc. (WRBY) P/S ratio
As of 5 November 2026, Warby Parker Inc. (WRBY) trades at a P/S ratio of 3.5×. Over the past ten years it has ranged from 1.8× (November 2023) to 7.2× (November 2021); the current reading is higher than 68% of that period. That is above the Medical Instruments & Supplies industry median of 2.5× and in line with the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 3.1× | (18.87%) |
| FY2024 | 3.8× | 44.69% |
| FY2023 | 2.6× | (5.17%) |
| FY2022 | 2.8× | (55.11%) |
| FY2021 | 6.1× | 1.58% |
| FY2020 | 6.0× | 0.00% |
| FY2019 | 6.0× | — |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 3.7× | (10.14%) |
| Jun 2026 | 4.1× | 41.24% |
| Mar 2026 | 2.9× | (4.74%) |
| Dec 2025 | 3.1× | (23.11%) |
| 22 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| XRAY DENTSPLY SIRONA Inc. compare | 0.6× |
| ICUI ICU Medical, Inc. compare | 1.9× |
| STVN Stevanato Group S.p.A. compare | 2.5× |
| AZTA Azenta, Inc. compare | 2.8× |
| WRBY Warby Parker Inc. | 3.5× |
| ATRC AtriCure, Inc. compare | 5.0× |
| LMAT LeMaitre Vascular, Inc. compare | 7.0× |
| KMTS Kestra Medical Technologies, Ltd. compare | 15.3× |
| PLSE Pulse Biosciences, Inc compare | 2,559× |
| Medical Instruments & Supplies industry median | 2.5× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on WRBY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement